1Attias, D ,Weitzman, S. The efficacy ofrituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Current Opinion in Pediatrics, 2008; 20(1) : 17-22.
2Culic S, Culic V, Annanda V, et al. Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl. Pediatric Hematology and Oncology, 2003; 20(4) : 339-344.
3Jetsrisuparb A, Wiangnon S, Komvilaisak P, et al. Rituximab Combined With CHOP For Successful Treatment of Aggressive Recurrent, Pediatric B-Cell Large Cell Non-Hodgkin' s Lymphoma. Journal of Pediatric Hematology/Oneology, 2005; 27 (4) : 223-226.
4Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carhoplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell ( CD20 + ) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children' s Oncology Group. Pediatr Blood Cancer, 2009; 52: 177-181.
5Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008; 111(12) : 5486-5495.
6Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med, 2007; 48(11) : 1767-1776.
7Gopal AK, Press OW, Wilbur SM, et al. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood, 2008; 112(3): 830-835.
8Stolz C, Hess G, Hahnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximah-induced apoptosis. Blood, 2008; 112(8): 3312-3321.
9Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood, 2004 ; 104 ( 12 ) : 3705-3711.
10Perkins SL, Lones MA, Davenport V, et al. B-Cell non-Hodgkin' s lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children' s cancer group report. Clin Adv Hematol Oncol, 2003 ; 1 (5) : 314-317.
